The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study

Autor: Banafshe Darvishi Teli, Aziz Rezapour, Meysam Behzadifar, Samad Azari, Seyed Jafar Ehsanzadeh, Masoud Behzadifar
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: BMC Research Notes, Vol 17, Iss 1, Pp 1-7 (2024)
Druh dokumentu: article
ISSN: 1756-0500
75604485
DOI: 10.1186/s13104-024-06913-6
Popis: Abstract Objective This study aims to assess the economic burden of prostate cancer in Iran by analyzing direct medical costs, direct non-medical costs, and indirect costs. We conducted a cross-sectional cost-of-illness study in Khorramabad, located in western Iran, during 2023, using a prevalence-based, bottom-up approach. Data were collected from 285 prostate cancer patients using questionnaires, interviews, and patient records. Results Our study estimated the economic burden of prostate cancer at $744,990. Direct medical costs accounted for 63.50% of this, totaling $153,330, with therapy being the largest component. Direct non-medical costs were $62,130, and indirect costs from productivity losses were $209,760. The calculated overall cost per patient was $2,614.88. Extrapolating from the 2021 Global Burden of Disease data, which reported approximately 83,000 prostate cancer patients in Iran, the national economic burden is estimated at $217,034,040. This substantial burden highlights the need for improved insurance coverage and early detection. The findings suggest that policymakers and healthcare providers in Iran should develop standardized cost analysis methods and enhance financial protection to alleviate economic strain and improve healthcare outcomes and sustainability.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje